Product Description
cell-culture derived smallpox vaccine; infects MRC-5 cells (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00336635)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Seoul National University Hospital
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Smallpox
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CJ_SPX_303 | P3 |
Completed |
Smallpox |
2011-07-01 |
|
CJ_SPX_302 | P3 |
Completed |
Smallpox |
2010-12-01 |
|
CJ_SPX_301 | P3 |
Completed |
Smallpox |
2008-06-01 |